Lisata Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview

Lisata Therapeutics

17/03/2023 11:43

* Lisata Therapeutics Inc  LSTA.OQ   LSTA.O  is expected
to show
no change in quarterly revenue when it reports  results on March
20 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Lisata Therapeutics
Inc
is for a loss of $1.01 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lisata
Therapeutics Inc is $15​, above​ its last closing price
of $3.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.90       -0.90      -7.88     Missed  -775.6
 Jun. 30 2022  -1.65       -1.45      -1.65     Missed  -13.8
 Mar. 31 2022  -1.42       -1.45      -1.05     Beat    27.6​
 Dec. 31 2021  -1.95       -2.17      -1.65     Beat    24.1
 ​​Sep.        -1.95       -2.25      -1.80     Beat    20
 30 2021                                                
 Jun. 30 2021  -2.17       -2.17      -1.50     Beat    31​
 Mar. 31 2021  -1.35       -1.27      -2.85     Missed  -123.5
 Dec. 31 2020  -4.08       -3.80      -4.20     Missed  -10.5
 This summary was machine generated March 17 at 11:43 GMT.  All
figures in US dollars  unless otherwise stated